MCID: PPL002
MIFTS: 46

Papillary Carcinoma

Categories: Cancer diseases

Aliases & Classifications for Papillary Carcinoma

MalaCards integrated aliases for Papillary Carcinoma:

Name: Papillary Carcinoma 12 15 17
Carcinoma, Papillary 44 70
Carcinoma Papillary 54

Classifications:



External Ids:

Disease Ontology 12 DOID:3113
MeSH 44 D002291
NCIt 50 C2927
SNOMED-CT 67 25910003
UMLS 70 C0007133

Summaries for Papillary Carcinoma

Disease Ontology : 12 A carcinoma that is derives from epithelial cells with finger like projections.

MalaCards based summary : Papillary Carcinoma, also known as carcinoma, papillary, is related to primary peritoneal carcinoma and breast papillary carcinoma. An important gene associated with Papillary Carcinoma is TG (Thyroglobulin), and among its related pathways/superpathways are Endometrial cancer and Pathways in cancer. The drugs BCG vaccine and Immunologic Factors have been mentioned in the context of this disorder. Affiliated tissues include thyroid, breast and lymph node, and related phenotypes are cellular and behavior/neurological

Related Diseases for Papillary Carcinoma

Diseases related to Papillary Carcinoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 674)
# Related Disease Score Top Affiliating Genes
1 primary peritoneal carcinoma 33.0 RET PGR ERBB2
2 breast papillary carcinoma 32.8 PGR ERBB2
3 multicentric papillary thyroid carcinoma 32.3 TG RET
4 tall cell variant papillary carcinoma 32.1 TG RET NKX2-1 MET LGALS3 KRT19
5 nonencapsulated sclerosing carcinoma 32.0 TPO TG RET CALCA
6 papillary serous adenocarcinoma 32.0 PGR PAX8 NKX2-1 KRT7 KRT20
7 in situ carcinoma 31.5 PGR MUC1 ERBB2
8 thyroid cancer, nonmedullary, 2 31.4 TSHR TG PAX8 LGALS3 CALCA BRAF
9 renal cell carcinoma, nonpapillary 31.3 RET PAX8 NKX2-1 MUC1 MET KRT7
10 thyroid tumor 31.3 RET BRAF
11 ductal carcinoma in situ 31.2 PGR MUC1 ERBB2
12 thyroiditis 31.2 TSHR TPO TG RET CALCA
13 parathyroid adenoma 31.0 RET LGALS3 CALCA
14 thyroid carcinoma, familial medullary 31.0 TG RET NKX2-1 CALCA BRAF
15 papillary adenocarcinoma 30.9 PGR NKX2-1 MUC1 KRT7 KRT19 ERBB2
16 benign mesothelioma 30.9 NKX2-1 KRT7 KRT20 KRT19
17 intraductal papilloma 30.9 PGR KRT7 ERBB2
18 thyroid carcinoma 30.8 TSHR TPO TG RET PAX8 NKX2-1
19 adenoma 30.8 TSHR TG RET MUC1 LGALS3 KRT7
20 multiple endocrine neoplasia 30.7 TG RET CALCA
21 hyperthyroidism 30.7 TSHR TPO TG CALCA
22 peritoneal mesothelioma 30.7 PGR MUC1 MET
23 graves' disease 30.6 TSHR TPO TG PAX8
24 metanephric adenoma 30.6 MUC1 KRT7 BRAF
25 transitional cell carcinoma 30.6 KRT7 KRT20 KRT19 ERBB2 BRAF
26 graves disease 1 30.6 TSHR TPO TG CALCA
27 thyroid gland medullary carcinoma 30.6 TG RET PAX8 NKX2-1 NCOA4 CCDC6
28 cystic teratoma 30.5 NKX2-1 KRT7 KRT20
29 mesothelioma, malignant 30.5 NKX2-1 MUC1 MET KRT7 KRT20
30 goiter 30.5 TSHR TPO TG RET PAX8 NKX2-1
31 malignant struma ovarii 30.5 TG RET NKX2-1 NCOA4 KRT19
32 mature teratoma 30.4 KRT7 ERBB2 BRAF
33 pneumothorax 30.4 PGR NKX2-1 MUC1
34 papillary transitional carcinoma 30.4 KRT7 KRT20
35 struma ovarii 30.4 TSHR TG RET NKX2-1 NCOA4 KRT19
36 multinodular goiter 30.4 TSHR TPO TG PAX8 NKX2-1 KRT19
37 renal cell carcinoma, papillary, 1 30.4 PAX8 MET KRT7 ERBB2 BRAF
38 hemangioma 30.4 RET PGR NKX2-1 MUC1 KRT7
39 bronchiolo-alveolar adenocarcinoma 30.4 NKX2-1 KRT7 KRT20
40 endometrial serous adenocarcinoma 30.4 PGR ERBB2 CLDN3
41 squamous cell carcinoma 30.4 MUC1 KRT7 KRT19 ERBB2 BRAF
42 adenocarcinoma 30.4 RET NKX2-1 MUC1 MET KRT7 KRT20
43 hypoparathyroidism 30.4 TPO RET CALCA
44 oncocytoma 30.4 NKX2-1 MUC1 KRT7 KRT20 KRT19
45 parathyroid carcinoma 30.4 RET LGALS3 CALCA
46 nonseminomatous germ cell tumor 30.3 ERBB2 BRAF
47 intrahepatic cholangiocarcinoma 30.3 MUC1 KRT7 KRT20 KRT19 ERBB2
48 cystadenoma 30.3 PGR MUC1 KRT7 KRT20
49 ectopic thymus 30.3 TG NKX2-1 CALCA
50 biliary papillomatosis 30.3 MUC1 KRT7

Graphical network of the top 20 diseases related to Papillary Carcinoma:



Diseases related to Papillary Carcinoma

Symptoms & Phenotypes for Papillary Carcinoma

MGI Mouse Phenotypes related to Papillary Carcinoma:

46
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.27 BRAF CLDN4 ERBB2 KRT19 KRT7 LGALS3
2 behavior/neurological MP:0005386 10.26 BRAF CLDN3 ERBB2 LGALS3 MET NKX2-1
3 homeostasis/metabolism MP:0005376 10.21 BRAF CLDN4 ERBB2 KRT7 LGALS3 MET
4 endocrine/exocrine gland MP:0005379 10.14 BRAF ERBB2 KRT19 MET NKX2-1 PAX8
5 digestive/alimentary MP:0005381 10.03 BRAF ERBB2 KRT19 LGALS3 MET NKX2-1
6 limbs/digits/tail MP:0005371 9.97 BRAF ERBB2 MET PAX8 PGR RET
7 neoplasm MP:0002006 9.91 BRAF ERBB2 KRT19 LGALS3 MET NKX2-1
8 normal MP:0002873 9.81 BRAF CLDN4 ERBB2 KRT19 MET NKX2-1
9 reproductive system MP:0005389 9.7 BRAF CLDN3 ERBB2 KRT19 LGALS3 NKX2-1
10 skeleton MP:0005390 9.32 BRAF ERBB2 KRT19 LGALS3 NKX2-1 PAX8

Drugs & Therapeutics for Papillary Carcinoma

Drugs for Papillary Carcinoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 57)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
BCG vaccine Approved, Investigational Phase 3
2 Immunologic Factors Phase 3
3 Adjuvants, Immunologic Phase 3
4 Vaccines Phase 3
5 Antibiotics, Antitubercular Phase 3
6 Mitomycins Phase 3
7 Alkylating Agents Phase 3
8 Anti-Bacterial Agents Phase 3
9
Hyaluronic acid Approved, Vet_approved Phase 2 9004-61-9 53477741
10
Durvalumab Approved, Investigational Phase 2 1428935-60-7
11
Ipilimumab Approved Phase 2 477202-00-9
12
nivolumab Approved Phase 2 946414-94-4
13
Iodine Approved, Investigational Phase 2 7553-56-2 807
14
Paclitaxel Approved, Vet_approved Phase 2 33069-62-4 36314
15
Lenvatinib Approved, Investigational Phase 2 417716-92-8
16
Pembrolizumab Approved Phase 2 1374853-91-4
17
Sunitinib Approved, Investigational Phase 2 557795-19-4, 341031-54-7 5329102
18
Lenalidomide Approved Phase 1, Phase 2 191732-72-6 216326
19
Trametinib Approved Phase 2 871700-17-3 11707110
20
Trastuzumab Approved, Investigational Phase 2 180288-69-1 9903
21
Carboplatin Approved Phase 2 41575-94-4 10339178 498142 38904
22
Tremelimumab Investigational Phase 2 745013-59-6
23
Cadexomer iodine Experimental Phase 2 94820-09-4
24
Cediranib Investigational Phase 1, Phase 2 288383-20-0 9933475
25
Maleic acid Experimental Phase 1, Phase 2 110-16-7 444266
26 Pharmaceutical Solutions Phase 2
27 Fluorides Phase 2
28 Antimetabolites Phase 2
29 Mitogens Phase 2
30 Fluorodeoxyglucose F18 Phase 2
31 Deoxyglucose Phase 2
32 Radiopharmaceuticals Phase 2
33 Antiviral Agents Phase 2
34 Endothelial Growth Factors Phase 2
35 Albumin-Bound Paclitaxel Phase 2
36 Antineoplastic Agents, Immunological Phase 2
37 Protein Kinase Inhibitors Phase 2
38 Trace Elements Phase 2
39 Nutrients Phase 2
40 Anti-Infective Agents, Local Phase 2
41 Anti-Infective Agents Phase 2
42 Micronutrients Phase 2
43 Angiogenesis Inhibitors Phase 2
44 Immunoglobulins Phase 2
45 Antibodies, Monoclonal Phase 2
46 Antibodies Phase 2
47 Tubulin Modulators Phase 2
48 Antimitotic Agents Phase 2
49
Iron Approved 7439-89-6 23925 29936
50
Parathyroid hormone Approved, Investigational 9002-64-6

Interventional clinical trials:

(show all 36)
# Name Status NCT ID Phase Drugs
1 Comparative Study of Intravesical BCG Standard Dose Long-Term Maintenance Versus BCG 1/3 Dose Long-Term Maintenance Versus BCG Standard Dose Short-Term Maintenance Versus BCG 1/3 Dose Short-Term Maintenance in Intermediate and High Risk Ta, T1 Papillary Carcinoma of the Urinary Bladder Completed NCT00002990 Phase 3
2 A Multicenter, Single-Arm Study Evaluating the Efficacy of Synergo® Radiofrequency-Induced Thermochemotherapy Effect (RITE) With Mitomycin C (Synergo® RITE + MMC) in CIS Non-Muscle Invasive Bladder Cancer (NMIBC) Bacillus Calmette-Guérin (BCG)-Unresponsive Patients With or Without Papillary NMIBC Terminated NCT03335059 Phase 3
3 ONCOFID-P-B (PACLITAXEL-HYALURONIC ACID) in the Intravescical Therapy of Patients With Non-muscle Invasive Cancer of the Bladder. A Phase II Marker Lesion. STUDY Completed NCT04661826 Phase 2 Oncofid-P-B
4 Phase II Study of Cabozantinib in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Who Progressed on Prior VEGFR-Targeted Therapy Completed NCT01811212 Phase 2 Cabozantinib S-malate
5 Phase 2 Study of Selumetinib Hydrogen Sulfate in Iodine-131 Refractory Papillary Thyroid Carcinoma and Papillary Thyroid Carcinoma With Follicular Elements Completed NCT00559949 Phase 2 Selumetinib
6 A Phase II Study of Single Agent Intravenous (IV) VEGF Trap in Patients With Poor Prognostic Recurrent and/or Metastatic Thyroid Cancer After RAI Therapy Completed NCT00729157 Phase 2
7 Utility of Preoperative FDG-PET/CT Scanning Prior to Primary Chemoradiation Therapy to Detect Retroperitoneal Lymph Node Metastasis in Patients With Locoregionally Advanced Carcinoma of the Cervix (IB2, IIA ≥ 4 CM, IIB-IVA) or Endometrium (Grade 3 Endometrioid Endometrial Carcinoma; Serous Papillary Carcinoma, Clear Cell Carcinoma, or Carcinosarcoma (Any Grade); and Grade 1 OR 2 Endometrioid Endometrial Carcinoma With Cervical Stromal Involvement Overt in Clinical Examination or Confirmed by Endocervical Curettage Completed NCT00416455 Phase 1, Phase 2 ferumoxtran-10
8 A Phase II Study of Durvalumab (MEDI4736) Plus Tremelimumab for the Treatment of Patients With Progressive, Refractory Advanced Thyroid Carcinoma - The DUTHY Trial Recruiting NCT03753919 Phase 2 Durvalumab;Tremelimumab
9 Phase II Study of XL184 (Cabozantinib) in Combination With Nivolumab and Ipilimumab (CaboNivoIpi) in Patients With Radioiodine-Refractory Differentiated Thyroid Cancer Whose Cancer Progressed After One Prior VEGFR-Targeted Therapy Recruiting NCT03914300 Phase 2 Cabozantinib S-malate
10 Pilot Study to Evaluate the Safety and Efficacy of Percutaneous Laser Ablation of Thyroid Papillary Microcarcinoma Recruiting NCT04623801 Phase 2
11 A Phase 2 Study of Lenvatinib in Combination With Radioactive Iodine Therapy in Patients With Progressive RAI-Sensitive Differentiated Thyroid Cancer Recruiting NCT03506048 Phase 2 Lenvatinib
12 Combination Targeted Therapy With Pembrolizumab and Lenvatinib in Progressive, Radioiodine-Refractory Differentiated Thyroid Cancers: A Phase II Study Active, not recruiting NCT02973997 Phase 2 Lenvatinib;Lenvatinib Mesylate
13 Phase II Trial of Sunitinib (SU11248) in Iodine-131 Refractory, Unresectable Differentiated Thyroid Cancers and Medullary Thyroid Cancers Active, not recruiting NCT00381641 Phase 2 Sunitinib;Sunitinib Malate
14 Phase I/II Trial of Cediranib Alone or Cediranib and Lenalidomide in Iodine 131-Refractory Differentiated Thyroid Cancer Active, not recruiting NCT01208051 Phase 1, Phase 2 Cediranib;Cediranib Maleate;Lenalidomide
15 A Phase 2 Study of Trametinib in Combination With Radioiodine (RAI) for RAS Mutant or RAS/RAF Wild-Type, RAI-Refractory Recurrent and/or Metastatic Thyroid Cancers Active, not recruiting NCT02152995 Phase 2 Trametinib
16 Randomized Double-Blind Phase II Study of Radioactive Iodine (RAI) in Combination With Placebo or Selumetinib for the Treatment of RAI-Avid Recurrent/Metastatic Thyroid Cancers Active, not recruiting NCT02393690 Phase 2 Selumetinib
17 Randomized Phase II Evaluation of Carboplatin/Paclitaxel With and Without Trastuzumab (Herceptin) in HER2/Neu+ Patients With Advance/Recurrent Uterine Serous Papillary Carcinoma Active, not recruiting NCT01367002 Phase 2 Carboplatin/Paclitaxel;Trastuzumab
18 NeoadjuvantTreatment With Selpercatinib in RET-Altered Thyroid Cancers Not yet recruiting NCT04759911 Phase 2 Selpercatinib
19 Phase II Study of Two Dose Levels of Toremifene in the Treatment of Chemotherapy-Resistant Papillary Carcinoma of the Ovary Withdrawn NCT00003865 Phase 2 toremifene
20 Prospective Study on the Clinical Prognosis of Bilateral Central Lymph Node Dissection in the Patients With Unilateral Thyroid Papillary Carcinoma Unknown status NCT02648399
21 Comparison Between the Axillary Bilateral-breast Approach (ABBA) and Bilateral Axillo-breast Approach (BABA) for Robotic Thyroidectomy Completed NCT02768753
22 Pre-Operative Nodal Staging of Thyroid Cancer Using Ultra-Small Superparamagnetic Iron Oxide Magnetic Resonance Imaging (USPIO MRI): Preliminary Study Completed NCT01927887 Ferumoxytol
23 Study of the Testicular Function After Iodine 131 Therapy in Patients With Papillary Carcinoma Completed NCT01150318 Administration of 131 iodine
24 Proper Extent of Surgery for Papillary Microcarcinoma Completed NCT01648569
25 Is Routine Dissection of Central Lymph Node Necessary for Papillary Thyroid Carcinoma, T1-2 N0? Recruiting NCT04336696
26 Effectiveness of Intraoperative Neuromonitoring of the External Branch of the Superior Laryngeal Nerve During Thyroid Surgery Recruiting NCT03773120
27 Near-infrared (NIR) Fluorescence Imaging With Indocyanine Green (ICG) for Identification of Sentinel Lymph Nodes and Parathyroid Glands During Total Thyroidectomy: Prospective Randomized Clinical Trial Recruiting NCT04424485
28 A Multicenter, Randomized and Controlled Trial of Radiofrequency Ablation vs. Conventional Surgery as Treatment of Papillary Thyroid Microcarcinoma (PTMC) Recruiting NCT03808779
29 Active Surveillance of Papillary Thyroid Microcarcinoma Recruiting NCT02609685
30 Prospective Active Surveillance Versus Surgery in Thyroid Papillary Microcarcinoma Recruiting NCT04129281
31 Radiofrequency Ablation of Low Risk Papillary Thyroid Microcarcinoma: Safety and Efficacy Recruiting NCT03432299
32 A Strategy to Search for Genes Predisposing to Papillary Carcinoma of the Thyroid When Mutated Recruiting NCT02776969
33 Active Surveillance on Papillary Thyroid Microcarcinoma Active, not recruiting NCT02938702
34 Correlation of Malignancy Predictors, Bethesda (I-VI) and TI-RADS Scores (I-V) With Final Histopathology in Patients Undergoing Total Thyroidectomy 34 Years After Chernobyl Disaster: Multi-centric Trial Enrolling by invitation NCT04411290
35 What is the Relation of Microbiome to Papillary Thyroid Microcarcinoma Development? Not yet recruiting NCT04376203
36 A Prospective Randomized Trial Comparing Ultrasound-guided High Intensity Focused Ultrasound (HIFU) Ablation With Active Surveillance (AS) in the Management of Low-risk Papillary Thyroid Microcarcinoma (PTMC) Suspended NCT03327636

Search NIH Clinical Center for Papillary Carcinoma

Cochrane evidence based reviews: carcinoma, papillary

Genetic Tests for Papillary Carcinoma

Anatomical Context for Papillary Carcinoma

MalaCards organs/tissues related to Papillary Carcinoma:

40
Thyroid, Breast, Lymph Node, Kidney, Ovary, Lung, Pancreas

Publications for Papillary Carcinoma

Articles related to Papillary Carcinoma:

(show top 50) (show all 5887)
# Title Authors PMID Year
1
Universal markers of thyroid malignancies: galectin-3, HBME-1, and cytokeratin-19. 54 61
20198455 2010
2
Absence of BRAF, NRAS, KRAS, HRAS mutations, and RET/PTC gene rearrangements distinguishes dominant nodules in Hashimoto thyroiditis from papillary thyroid carcinomas. 54 61
20012784 2010
3
Follicular variant of papillary carcinoma: reproducibility of histologic diagnosis and utility of HBME-1 immunohistochemistry and BRAF mutational analysis as diagnostic adjuncts. 54 61
20042852 2010
4
Adult onset Still's disease diagnosed concomitantly with occult papillary thyroid cancer: paraneoplastic manifestation or coincidence? 61 54
19847590 2010
5
Napsin A and thyroid transcription factor-1 expression in carcinomas of the lung, breast, pancreas, colon, kidney, thyroid, and malignant mesothelioma. 54 61
19740516 2010
6
BRAF mutational analysis in papillary carcinomas with mixed follicular and papillary growth patterns. 61 54
19738460 2009
7
Papillary carcinoma of the breast lacks evidence of RET rearrangements despite morphological similarities to papillary thyroid carcinoma. 54 61
19543246 2009
8
COX-2 is induced by HGF stimulation in Met-positive thyroid papillary carcinoma cells and is involved in tumour invasiveness. 61 54
19391129 2009
9
Development and characterization of a human single-chain antibody fragment against claudin-3: a novel therapeutic target in ovarian and uterine carcinomas. 61 54
19426958 2009
10
Epigenetic silencing of TTF-1/NKX2-1 through DNA hypermethylation and histone H3 modulation in thyroid carcinomas. 61 54
19506552 2009
11
The T1799A BRAF mutation is absent in cribriform-morular variant of papillary carcinoma. 54 61
19415957 2009
12
The role of immunohistochemistry in the differential diagnosis of papillary lesions of the breast. 61 54
19126567 2009
13
Immunohistochemical analysis of nm23 protein expression in thyroid papillary carcinoma and follicular neoplasm. 61 54
18996649 2009
14
Differential expression of CK 19 in follicular adenoma, well-differentiated tumour of uncertain malignant potential (WDT-UMP) and follicular variant of papillary carcinoma. 54 61
19213370 2009
15
A case of black thyroid associated with hyalinizing trabecular tumor. 54 61
18753707 2008
16
Coexistence of primary squamous cell carcinoma of thyroid with classic papillary thyroid carcinoma. 61 54
19067856 2008
17
Thyroid peroxidase and galectin-3 immunostaining in differentiated thyroid carcinoma with clinicopathologic correlation. 61 54
18657294 2008
18
Serous carcinoma of the uterus-determination of HER-2/neu status using immunohistochemistry, chromogenic in situ hybridization, and quantitative polymerase chain reaction techniques: its significance and clinical correlation. 54 61
18248390 2008
19
Cytoplasmic and serum galectin-3 in diagnosis of thyroid malignancies. 54 61
18809382 2008
20
Cyclin D1 and p27 expression as prognostic factor in papillary carcinoma of thyroid: association with clinicopathological parameters. 61 54
18925698 2008
21
Potential diagnostic markers in nodular lesions of the thyroid gland: an immunohistochemical study. 54 61
18795075 2008
22
Claudin-3 and claudin-4 expression in serous papillary, clear-cell, and endometrioid endometrial cancer. 54 61
18313739 2008
23
Thyroid carcinoma: molecular pathways and therapeutic targets. 54 61
18437172 2008
24
Split sample comparison of a liquid-based method and conventional smears in thyroid fine needle aspiration. 61 54
18540296 2008
25
[A case of omental mesothelioma presenting with laminar thickening of omentum-appearances of diffuse malignant peritoneal mesothelioma]. 61 54
18408444 2008
26
Expression of cytokeratin 19 in the diagnosis of thyroid papillary carcinoma by quantitative polymerase chain reaction. 61 54
18308654 2008
27
Application of CD56, P63 and CK19 immunohistochemistry in the diagnosis of papillary carcinoma of the thyroid. 54 61
18254952 2008
28
HER-2/neu overexpression and amplification in uterine serous papillary carcinoma: comparative analysis of immunohistochemistry, real-time reverse transcription-polymerase chain reaction, and fluorescence in situ hybridization. 54 61
17451461 2008
29
[Galectin-3 in diagnosis of thyroid cancer]. 54 61
18652236 2008
30
Molecular detection of PPAR gamma rearrangements and thyroid carcinoma in preoperative fine-needle aspiration biopsies. 54 61
18688583 2008
31
Differential expression of dysadherin in papillary thyroid carcinoma and microcarcinoma: correlation with E-cadherin. 61 54
18677652 2008
32
Iodine-123 uptake in vertebral haemangiomas in a patient with papillary thyroid carcinoma. 54 61
19173186 2008
33
Galectin-3 expression in tumor progression and metastasis of papillary thyroid carcinoma. 61 54
18581271 2008
34
The histological diagnosis of metastases to the breast from extramammary malignancies. 61 54
18042689 2007
35
Diagnostic value of galectin-3, HBME-1, cytokeratin 19, high molecular weight cytokeratin, cyclin D1 and p27(kip1) in the differential diagnosis of thyroid nodules. 54 61
17728499 2007
36
h-caldesmon, calretinin, estrogen receptor, and Ber-EP4: a useful combination of immunohistochemical markers for differentiating epithelioid peritoneal mesothelioma from serous papillary carcinoma of the ovary. 54 61
17667535 2007
37
Immunohistochemical staining of papillary breast lesions. 61 54
17525625 2007
38
Activating transcription factor-1-mediated hepatocyte growth factor-induced down-regulation of thrombospondin-1 expression leads to thyroid cancer cell invasion. 54 61
17409099 2007
39
Prognostic significance of the MUC1 and MUC4 expressions in thyroid papillary carcinoma. 61 54
17473695 2007
40
Overexpression of claudin-3 and claudin-4 receptors in uterine serous papillary carcinoma: novel targets for a type-specific therapy using Clostridium perfringens enterotoxin (CPE). 54 61
17326053 2007
41
Double immunostaining with p63 and high-molecular-weight cytokeratins distinguishes borderline papillary lesions of the breast. 54 61
17295644 2007
42
The role of immunohistochemistry for smooth-muscle actin, p63, CD10 and cytokeratin 14 in the differential diagnosis of papillary lesions of the breast. 54 61
16698948 2007
43
Annexin-I as a potential target for green tea extract induced actin remodeling. 54 61
17019707 2007
44
The role of immunolocalization of CD57 and GLUT-1 in cell blocks in fine-needle aspiration diagnosis of papillary thyroid carcinoma. 61 54
16944537 2006
45
Analysis of differential BRAF(V600E) mutational status in multifocal papillary thyroid carcinoma: evidence of independent clonal origin in distinct tumor foci. 61 54
16983703 2006
46
Proteomic identification of new biomarkers and application in thyroid cytology. 61 54
17017437 2006
47
New molecular targeted therapies in thyroid cancer. 54 61
16940797 2006
48
Utility of galectin 3 expression in thyroid aspirates as a diagnostic marker in differentiating benign from malignant thyroid neoplasms. 61 54
17001889 2006
49
GLUT1 and p63 expression in endometrial intraepithelial and uterine serous papillary carcinoma. 61 54
16842248 2006
50
Annexin-1 downregulation in thyroid cancer correlates to the degree of tumor differentiation. 61 54
16627980 2006

Variations for Papillary Carcinoma

Expression for Papillary Carcinoma

Search GEO for disease gene expression data for Papillary Carcinoma.

Pathways for Papillary Carcinoma

GO Terms for Papillary Carcinoma

Cellular components related to Papillary Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 receptor complex GO:0043235 9.56 TSHR RET MET ERBB2
2 integral component of plasma membrane GO:0005887 9.56 TSHR TPO RET MUC1 MET ERBB2
3 basal plasma membrane GO:0009925 9.33 MET ERBB2 CLDN4
4 apicolateral plasma membrane GO:0016327 8.8 KRT19 CLDN4 CLDN3

Biological processes related to Papillary Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 positive regulation of gene expression GO:0010628 9.8 RET NKX2-1 ERBB2 CLDN3 BRAF
2 MAPK cascade GO:0000165 9.73 RET MET ERBB2 BRAF
3 positive regulation of kinase activity GO:0033674 9.5 RET MET ERBB2
4 peptidyl-tyrosine phosphorylation GO:0018108 9.46 RET MET ERBB2 BRAF
5 hormone biosynthetic process GO:0042446 9.37 TPO TG
6 positive regulation of metallopeptidase activity GO:1905050 9.26 CLDN4 CLDN3
7 thyroid-stimulating hormone signaling pathway GO:0038194 8.96 TSHR PAX8
8 thyroid gland development GO:0030878 8.92 TG PAX8 NKX2-1 BRAF

Molecular functions related to Papillary Carcinoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 protein binding GO:0005515 10.35 TSHR TG RET PGR PAX8 NKX2-1
2 structural molecule activity GO:0005198 9.62 KRT20 KRT19 CLDN4 CLDN3
3 identical protein binding GO:0042802 9.61 TG PGR MET ERBB2 CLDN4 CLDN3
4 protein phosphatase binding GO:0019903 9.58 MET LGALS3 ERBB2
5 protein tyrosine kinase activity GO:0004713 9.46 RET MET ERBB2 BRAF
6 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.43 RET MET ERBB2
7 thyroid-stimulating hormone receptor activity GO:0004996 8.62 TSHR PAX8

Sources for Papillary Carcinoma

3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 EFO
18 ExPASy
19 FMA
20 GARD
28 GO
29 GTR
30 HMDB
31 HPO
32 ICD10
33 ICD10 via Orphanet
34 ICD9CM
35 IUPHAR
36 KEGG
37 LifeMap
39 LOVD
41 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
53 NINDS
54 Novoseek
56 OMIM via Orphanet
57 OMIM® (Updated 05-Apr-2021)
61 PubMed
63 QIAGEN
68 SNOMED-CT via HPO
69 Tocris
70 UMLS
71 UMLS via Orphanet
Content
Loading form....